An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303

Eisai

Status

Conditions: Lennox Gastaut Syndrome

Treatments: Drug: Rufinamide

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT03778424

E2080-E044-501

Details and patient eligibility

About

This is an extended access study for participants who have completed Rufinamide Study E2080-G000-303 to continue to have access to rufinamide until it becomes commercially available in Poland or until no participants remain in the EAP.

Sex: All

Ages: 4+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants who were on rufinamide treatment and have completed Study E2080-G000-303 in Poland.

Exclusion criteria

• Participants were randomized to the other antiepileptic drug (AED) treatment group in study E2080-G000-303.